The present disclosure is related to novel solid forms of rifaximin, particularly co-crystals and co-morphs of rifaximin and a co-former selected from the group comprising carboxylic acids, amino acids, phenolic compounds and biotin. The new solid forms of rifaximin have a different solubility than that of the polymorph rifaximin K and rifaximin.